Verified by AISci
Public source attached
Source status for this paper in the current AISci reviewed snapshot.
- Primary source
- Hanif Medisiana Publisher
- Correction status
- none
- Evidence coverage
- 1 sources / 1 publishers
- Last metadata check
- Jul 19, 2026
paperBiotech
Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall
Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall
Source-permitted summary
Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall
SourceHanif Medisiana PublisherAI Reading Notes
Core signal
Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.
- Core signal
- Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall
- Field context
- Genomics and Gene Editing
- People and labs
- Not stated in the reviewed source.
- Why it matters
- Recent source-backed research output for AISci Stage A browsing.
- Limits to check
- AISci rank score does not assess scientific quality or citation impact.
Research Workflow
Research Workflow
Recommended next steps for turning this signal into research action.
- Read original source
- Check DOI/OpenAlex
- Open relationship graph
- Review people and labs: Not stated in the reviewed source.
- Open linked event for AISci context
- Prepare journal-club PPT: AISci action coming next
- Plan replication checks: AISci action coming next
Publication facts
- Type
- paperSourceHanif Medisiana Publisher
- Date
- Jun 19, 2026SourceHanif Medisiana Publisher
- Venue
- Sriwijaya Journal of OphthalmologySourceHanif Medisiana Publisher
- Open access
- unknownSourceHanif Medisiana Publisher
External IDs
Author order
No reviewed author edge is attached to this output.
Organizations
No source-confirmed author affiliation is attached.
Related events
Topics
Relationship evidence
Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall
Publication signal: Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall
Genomics and Gene Editing
Controlled AISci Stage A topic for Genomics and Gene Editing.
Timeline
- paperSafety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall